A FOXA1/SPDEF Co-regulatory Axis Drives ERBB2 and Suppresses TEAD/YAP-Driven EMT to Maintain Luminal Identity in HER2+ Breast Cancer
Jeong, J.; Lee, J.; Kim, S.; Lim, J.; Shin, J.; Yoo, K.; Kim, J.; Tanaka, Y.; Tae, H. S.; Kim, L. K.; Park, I.-H.; Wysolmerski, J.; choi, j.
Show abstract
The function of the pioneer factor forkhead box A1 (FOXA1) in estrogen receptor (ER)-negative, human epidermal growth factor receptor 2 (HER2, encoded by the ERBB2 gene)-positive breast cancer represents a critical gap in our understanding of lineage identity in tumorigenesis. Here, we solve this enigma by addressing this question through the identification of an indispensable, co-dependent regulatory circuit formed between FOXA1 and the SAM pointed domain containing ETS-family transcription factor (SPDEF). Using integrative multi-omics analyses of patient tumors and experimental models, we demonstrate that this circuit functions as the master guardian of the HER2-positive luminal state. It executes this role via two distinct, essential mechanisms: it directly binds regulatory elements to drive high-level expression of the ERBB2 oncogene, and it simultaneously preserves epithelial identity by suppressing a latent program of epithelial-to-mesenchymal transition (EMT). Mechanistically, the FOXA1/SPDEF circuit promotes the expression of the transcriptional repressor TRPS1, which in turn antagonizes the pro-mesenchymal activity of the TEAD/YAP complex. Our findings define a central regulatory node that couples lineage fidelity to oncogenic output in HER2-positive cancer, revealing the FOXA1/SPDEF-TRPS1 axis as a critical determinant of tumor plasticity and a potential therapeutic target for overcoming resistance in HER2-positive breast cancer.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Neoplastic immune mimicry potentiates breast tumor progression 97%
- Pan-cancer Drivers are Recurrent Transcriptional Regulatory Heterogeneities in Early-stage Luminal Breast Cancer 96%
- Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression and drug response 96%
Similar papers in this journal
- A recurrent pathogenic BRCA2 truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcription 96%
- MaTAR25 LncRNA Regulates the Tensin1 Gene to Impact Breast Cancer Progression 95%
- A pan-cancer analysis of CpG Island gene regulation reveals extensive plasticity within Polycomb targets 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.